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(AT: MCT 20.4 vs. M/A 24.0, Dct: MCT 1474.0 vs. M/A 898.6, p b 0.005).
By histological analysis, pulmonary vascular remodeling induced by
MCT was also inhibited (vessel wall thickness: MCT 0.44 vs. M/A 0.31,
p b 0.001). MCT treatment increased mRNA levels of endothelin (ET)
receptor-A, ET receptor-B, ET-1 and transforming growth factor (TGF)-
beta in the lung. ADRCs therapy suppressed these increased mRNA
(p b 0.05).
Conclusion ADRC therapy inhibited the development of PAH by
reversing the changes in ET expression and inﬂammatory cytokines.
These ﬁndings suggest that ADRC therapy may open a novel strategy
to treat PAH.
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Pulmonary hypertension (PH) is an unremitting disease deﬁned by a
progressive increase in pulmonary vascular resistance leading to right-
sided heart failure. Using ECE1 knockout mice (ECE1+/−) we
demonstrated here that heterozygous deﬁciency of ECE1 protects mice
against PH, RV hypertrophy, and pulmonary vascular remodeling on 3
weeks of exposure to hypoxia. We also observed that chronic hypoxia-
induced PH is not only associated with increased levels of systemic and
pulmonary endothelin-1, but also associated with diminished level of
bradykinin (BK) peptide in lung. Genetic inactivation of ECE1 did not
affect ET-1 levels but prevented the degradation of BK in lungs during
hypoxia-induced PH. The clinical relevance of the data was indicated by
our observation that the level of plasma BK in the pulmonary vein (PV )
of patients with pulmonary hypertension due to atrial septal de-
fect (ASD-PH) is signiﬁcantly lower than in ASD patients without
pulmonary hypertension (ASD-PH: 14.0 ± 7.2 ng/mL; ASD-noPH: 24.3
± 20.8 ng/mL; p b 0.05). Furthermore, plasma BK level in PV has
signiﬁcant correlation with some hemodynamic parameters in this
patient group (i.e. the pulmonary cardiac output, the ratio of pulmonary/
systemic cardiac output and the systemic vascular resistance). Together,
these data show that inhibition of ECE1 is protective against the
development pulmonary hypertension through the preservation of
bradykinin action. This study also showed that bradykinin level was
diminished in PH and was correlated signiﬁcantly with some hemody-
namic parameters in mice and patients with PH, indicating BK as a
promising therapeutical target for PH.
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Background: Idiopathic/heritable pulmonary arterial hypertension
(I/HPAH) is reported to have a poor prognosis despite the available
therapeutic options. Although there are reports on survival of patients
fromWestern countries, there is a shortage of data from Asia.
Methods: A retrospective chart reviewwas performed on 56 patients
with I/HPAH. Survival analysis was conducted by using Kaplan- Meier
method and differences between parameters measured at baseline and
after treatment were tested by the paired t-test. Results: There are 41
females (73%) and 15 males (27%) included in this study. The mean age
was 32 ± 17 years old at the time of diagnosis. Mean survival time from
diagnosis was 14.5 ± 0.8 years (95% CI, 12.9-16.2 years), with 1-, 2-, 3-,
5- and 10-year survival rates of 100, 96, 96, 96 and 78%. In patients who
underwent follow-up right heart catheterization at least 3 months later
from the ﬁrst catheterization at our hospital, WHO functional class
improved from 3 to 2 (P b 0.01), and mean pulmonary arterial pressure
was decreased from 63.2 ± 15.0 to 34.8 ± 10.3 mmHg (P b 0.01).
Cardiac index was improved from 2.3 ± 0.8 to 3.5 ± 0.9 L/min/m2
(P b 0.01). At follow-up, 98% of patients were on PAH-targeted drugs:
prostacyclin analogue (n= 52, 93%), endothelin receptor antagonists
(n= 38, 68%), and phosphodiesterase type 5 inhibitors (n = 29, 52%).
Forty-two patients (75%) were treated with combination therapy.
Conclusions: The study revealed a better survival of Japanese
patients with I/HPAH than ever reported. Hemodynamic parameters
were signiﬁcantly improved. It might be caused by the difference
of ethnicity or high prescription rates of targeted drugs used to treat
I/HPAH.
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